PTO/SB/08a (05-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10534922
Filing Date	2006-01-30
First Named Inventor	Philip John Hogg
Art Unit	1614
Examiner Name	Christopher R. Stone
Attorney Docket Number	05-363

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	7498406		2009-03-03	Hogg et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] ¡	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	02/074305	WO	A1	2002-09-26	Unisearch Ltd.		☐
	2	03/003011	WO	A1	2003-01-19	Unisearch Ltd.		☐
	3	03/039564	WO	A1	2003-05-15	Unisearch Ltd.		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10534922
	Filing Date	2006-01-30
	First Named Inventor	Philip John Hogg
	Art Unit	1614
	Examiner Name	Christopher R. Stone
	Attorney Docket Number	05-363

	4	04/042079	WO	A1	2004-05-21	Unisearch Ltd.		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	ALLEN et al., "The mounse Bcrpl/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin", Cancer Res., 1999, Vol. 59, 4237-4241.	☐
	2	DILDA et al., "Para to ortho repositioning of the arsenical moiety of the angiogenesis inhibitor 4-(N-(S-glutathionylacetyl)amino)phenylarsenoxide results in a markedly increased cellular accumulation and antiproliferative activity", Cancer Res., 2005, Vol. 65, 11729-11734.	☐
	3	DILDA et al., "Mechanism of selectivity of an angiogenesis inhibitor from screening a genome-wide set of Saccharomyces cerevisiae deletion strains", J. Natl. Cancer Institute, 2005, Vol. 97, 1539-1547.	☐
	4	DON et al., "A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells", Cancer Cell, 2003, Vol. 3, 497-509.	☐
	5	EVENS et al., "The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future", Leuk. Res., 2004, Vol. 28, 891-900.	☐
	6	EVERS et al., Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport", Br. J. Cancer, 2000, Vol. 83, 366-374.	☐
	7	KOBAYASHI et al., "Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane", J. Pharmacol. Exp. Ther., 2003, Vol. 306, 703-708.	☐
	8	KOOL et al., "MRP3, an organic anion transporter able to transport anti-cancer drugs", Proc. Natl. Acad. Sci., 1999, Vol. 96, 6914-6919.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10534922
	Filing Date	2006-01-30
	First Named Inventor	Philip John Hogg
	Art Unit	1614
	Examiner Name	Christopher R. Stone
	Attorney Docket Number	05-363

	9	REITER et al., "Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukemia", Acta Haematol., 2004, Vol. 112, 55-67.	☐
	10	VEY et al., "Arsenic trioxide for the treatment of myelodysplastic syndromes", Expert Opin. Pharmacother., 2004, Vol. 5, 613-621.	☐
	11	WOLFF et al., "Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer", Clin. Cancer Res., 2004, Vol. 10, 3528-3534.	☐
	12	US Patent Application Serial No. 12/513,159 filed on April 30, 2009.	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.